nach oben

Medical Microbiology and Immunology

Erschienen in:

01.02.2014 | Original Investigation

Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing

verfasst von: Heng Liu, Jacqueline de Vries-Idema, Wouter ter Veer, Jan Wilschut, Anke Huckriede

Erschienen in: Medical Microbiology and Immunology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Adjuvants can stimulate vaccine-induced immune responses and can contribute decisively to antigen dose sparing when vaccine antigen production is limited, as for example during a pandemic influenza outbreak. We earlier showed that GPI-0100, a semi-synthetic saponin derivative with amphiphilic structure, significantly stimulates the immunogenicity and protective efficacy of influenza subunit vaccine administered via a systemic route. Here, we evaluated the adjuvant effect of GPI-0100 on a virosomal influenza vaccine formulation. In contrast to influenza subunit vaccine adjuvanted with GPI-0100, virosomal vaccine supplemented with the same dose of GPI-0100 provided full protection of mice against infection at the extremely low antigen dose of 2 × 8 ng hemagglutinin. Overall, adjuvanted virosomes elicited higher antibody and T-cell responses than did adjuvanted subunit vaccine. The enhanced immunogenicity of the GPI-0100-adjuvanted virosomes, particularly at low antigen doses, is possibly due to a physical association of the amphiphilic adjuvant with the virosomal membrane. These results show that a combination of GPI-0100 and a virosomal influenza vaccine formulation is highly immunogenic and allows the use of very low antigen doses without compromising the protective potential of the vaccine.

Subbarao K, Joseph T (2007) Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 7:267–278PubMedCrossRef

Ellebedy AH, Webby RJ (2009) Influenza vaccines. Vaccine 27(Suppl 4):D65–D68PubMedCentralPubMedCrossRef

Nichol KL, Treanor JJ (2006) Vaccines for seasonal and pandemic influenza. J Infect Dis 194(Suppl 2):S111–S118PubMedCrossRef

Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD (2011) Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 29:5785–5792PubMedCrossRef

Beyer WE, Palache AM, Osterhaus AD (1998) Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig 15:1–12PubMedCrossRef

Leroux-Roels G (2010) Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28(Suppl 3):C25–C36PubMedCrossRef

Durando P, Iudici R, Alicino C, Alberti M, de Florentis D, Ansaldi F et al (2011) Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin 7(Suppl):29–40PubMedCrossRef

Liu H, Bungener L, ter Veer W, Coller BA, Wilschut J, Huckriede A (2011) Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines. Vaccine 29:2037–2043PubMedCrossRef

Liu H, Patil HP, de Vries-Idema J, Wilschut J, Huckriede A (2012) Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100. PLoS ONE 7:e52135PubMedCentralPubMedCrossRef

10.

Liu H, Patil HP, de Vries-Idema J, Wilschut J, Huckriede A (2013) Evaluation of mucosal and systemic immune responses elicited by GPI-0100-adjuvanted influenza vaccine delivered by different immunization strategies. PlosOne 8:e69649CrossRef

11.

Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, Lanteigne AM et al (2012) Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol 19:209–218PubMedCentralPubMedCrossRef

12.

Marciani DJ, Press JB, Reynolds RC, Pathak AK, Pathak V, Gundy LE et al (2000) Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 18:3141–3151PubMedCrossRef

13.

Marciani DJ, Reynolds RC, Pathak AK, Finley-Woodman K, May RD (2003) Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine 21:3961–3971PubMedCrossRef

14.

Huckriede A, Bungener L, Daemen T, Wilschut J (2003) Influenza virosomes in vaccine development. Methods Enzymol 373:74–91PubMedCrossRef

15.

Stegmann T, Morselt HW, Booy FP, van Breemen JF, Scherphof G, Wilschut J (1987) Functional reconstitution of influenza virus envelopes. EMBO J 6:2651–2659PubMed

16.

Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T (2005) Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23:1232–1241PubMedCrossRef

17.

Wilschut J (2009) Influenza vaccines: the virosome concept. Immunol Lett 122:118–121PubMedCrossRef

18.

Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T et al (2002) Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20:2287–2295PubMedCrossRef

19.

Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM et al (2005) The virosome concept for influenza vaccines. Vaccine 23(Suppl 1):S26–S38PubMedCrossRef

20.

Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr (1994) Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344:160–163PubMedCrossRef

21.

Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkel B et al (1997) Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15:1675–1679PubMedCrossRef

22.

Schaad UB, Buhlmann U, Burger R, Ruedeberg A, Wilder-Smith A, Rutishauser M et al (2000) Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 44:1163–1167PubMedCentralPubMedCrossRef

23.

Kanra G, Marchisio P, Feiterna-Sperling C, Gaedicke G, Lazar H, Durrer P et al (2004) Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 23:300–306PubMedCrossRef

24.

de Bruijn IA, Nauta J, Cramer WC, Gerez L, Palache AM (2005) Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 23(Suppl 1):S39–S49PubMedCrossRef

25.

Herzog C, Hartmann K, Kunzi V, Kursteiner O, Mischler R, Lazar H et al (2009) Eleven years of Inflexal V—a virosomal adjuvanted influenza vaccine. Vaccine 27:4381–4387PubMedCrossRef

26.

Calcagnile S, Zuccotti GV (2010) The virosomal adjuvanted influenza vaccine. Expert Opin Biol Ther 10:191–200PubMedCrossRef

27.

Esposito S, Marchisio P, Montinaro V, Bianchini S, Weverling GJ, Pariani E et al (2012) The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥ 6 to < 36 months: data from a randomized, phase III study. Vaccine 30:7005–7012PubMedCrossRef

28.

de Vries JJ, Bungener L, Ter Veer W, van Alphen L, van der Ley P, Wilschut J et al (2009) Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine 27:947–955PubMedCrossRef

29.

Peterson GL (1977) A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83:346–356PubMedCrossRef

30.

Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) ISCOM-based vaccines: the second decade. Immunol Cell Biol 83:119–128PubMedCrossRef

31.

Sun HX, Xie Y, Ye YP (2009) ISCOMs and ISCOMATRIX. Vaccine 27:4388–4401PubMedCrossRef

32.

Deliyannis G, Jackson DC, Dyer W, Bates J, Coulter A, Harling-McNabb L et al (1998) Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine 16:2058–2068PubMedCrossRef

33.

Sambhara S, Woods S, Arpino R, Kurichh A, Tamane A, Underdown B et al (1998) Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J Infect Dis 177:1266–1274PubMedCrossRef

34.

Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A (2012) Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS ONE 7:e36812PubMedCentralPubMedCrossRef

35.

Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J (2010) Lipopeptide-adjuvanted respiratory syncytial virus virosomes: a safe and immunogenic non-replicating vaccine formulation. Vaccine 28:5543–5550PubMedCrossRef

36.

Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L et al (2011) Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 29:8049–8059PubMedCrossRef

37.

Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ (2011) Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi Viruses 5:426–437CrossRef

38.

Madhun AS, Haaheim LR, Nilsen MV, Cox RJ (2009) Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 27:7367–7376PubMedCrossRef

39.

Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B et al (2008) TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26:1626–1637PubMedCrossRef

40.

Hamdy S, Elamanchili P, Alshamsan A, Molavi O, Satou T, Samuel J (2007) Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D, L-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 81:652–662PubMedCrossRef

Titel: Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing
verfasst von: Heng Liu
Jacqueline de Vries-Idema
Wouter ter Veer
Jan Wilschut
Anke Huckriede
Publikationsdatum: 01.02.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Medical Microbiology and Immunology / Ausgabe 1/2014
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-013-0313-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Anti-biofilm activity of low-molecular weight chitosan hydrogel against Candida species

Utility of serodiagnostics designed for use in the United States for detection of Lyme borreliosis acquired in Europe and vice versa

Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients

HIV-1 progression links with viral genetic variability and subtype, and patient’s HLA type: analysis of a Nairobi-Kenyan cohort

Prevalence of antibodies to European porcine influenza viruses in humans living in high pig density areas of Germany